What's new? Log in Free sign up

Filing search / Absci Corporation / "Strategy"

Search information

Absci Corporation

Companies

"Strategy"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

40 results

Newest first Best match first

ABSI Absci Corporation

Quarterly report

strategy; our expectations and estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain … development strategy to drive adoption of our Integrated Drug Creation platform by new and existing partners; develop, acquire, in-license

14 Aug 24

4:08pm

ABSI Absci Corporation

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

in an efficient manner, create a successful development strategy related to such candidates and design and develop differentiated therapeutics to treat disease … development strategy, the progress and timing for various stages of development including candidate selection, IND enabling studies, initiating clinical

ABSI Absci Corporation

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

statements, including statements regarding our strategy, estimated speed, cost advantages, improved success rates, and expanded intellectual property … strategy, the progress and timing for various stages of development including candidate selection, IND enabling studies, initiating clinical trials

ABSI Absci Corporation

Quarterly report

, including as we: implement an effective business development strategy to drive adoption of our Integrated Drug Creation platform by new and existing partners … . Increase the number of programs under existing partnerships: The execution of our long-term strategy relies substantially on the value our partners

14 May 24

7:35am

ABSI Absci Corporation

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

internal therapeutic asset programs, including our clinical development strategy, the progress, milestones and success of our internal asset programs

t1ssguchlp acu0mkg

Annual report to shareholders

Definitive proxy

23 Apr 24

4:08pm

21 Mar 24

7:33am

vhqyuarhz25mcbj8ey2b

Prospectus supplement for primary offering

buf cpgz5y8sac51965h

Results of Operations and Financial Condition

Prospectus supplement for primary offering

d15zywo8jtuc8k0l

Absci Corporation 2024 All Rights Reserved 42ND JP Morgan Healthcare Conference

Quarterly report

14 Nov 23

4:43pm

7b3hivimoe1r78m

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Quarterly report

14 Aug 23

8:11am

r3i04b1bp9 pz5y608bv

Departure of Directors or Certain Officers

y2k47x3wg gu5qu

Quarterly report

15 May 23

4:09pm

Annual report to shareholders

Definitive proxy

28 Apr 23

12:00am

sllofwxf91o48t8xb

Preliminary proxy

Prev
1
2
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.